Background/Aim: Our research hypothesis is that long-term acid suppression can lead to higher
susceptibility to Mycobacterium tuberculosis infection due to defective gastric acid barrier. Our
study aim was to determine the prevalence of long-term acid suppressive therapy use among
patients with Mtb infection and to explore its contribution to the development of infection.
Patients and Methods: A case-control study included 264 patients with newly diagnosed, pulmonary
or extrapulmonary TB, consecutively, and an equal number of normal subjects as a control group.
For all the enrolled, clinical evaluation (medical history and physical examination), abdominal
ultrasonography, chest radiography, and laboratory evaluation were provided. Long-term use of
acid suppressive therapy was defined as the use for three months or more, during the year preceding
the diagnosis of TB.
Results: The study groups were matching regarding age and gender. The most frequent type was
pulmonary TB (65.2%). Omeprazole was the most frequently used acid suppressive agent (39.6%).
Factors associated with Mtb infection were diabetes mellitus, chronic obstructive pulmonary disease,
long-term corticosteroids use, long-term acid suppressive therapy, liver cirrhosis, renal failure, and
congestive heart failure. After adjusting for the cofounding variables, long-term acid suppressive
therapy had adjusted or of 2.1 (95% CI 1.4-6.1; p 0.024) for its use among the study cases.
Conclusions: In conclusion, the wide use of acid suppressive therapy for long durations (especially
PPI) can make the patients more vulnerable to infection with Mtb.
Research Department
Research Journal
Annals of Digestive and Liver Disease
Research Member
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018
Research_Pages
NULL
Research Abstract